Zynerba Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
March 14 2018 - 9:00AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage
specialty neuropsychiatric pharmaceutical company dedicated to
developing and commercializing innovative pharmaceutically-produced
transdermal cannabinoid treatments for rare and near-rare
neurological and psychiatric disorders with high unmet medical
needs, today announced that Zynerba’s Chief Executive Officer,
Armando Anido will present a company overview at the Oppenheimer
28th Annual Healthcare Conference on Wednesday March 21, 2018 at
8:35 AM ET at the Westin New York Grand Central hotel in New York,
NY.
A live webcast of the presentation will be
accessible on the Investor Relations page of
http://www.zynerba.com. A replay of the webcast will be available
for 90 days following the conclusion of the event.
About Zynerba Pharmaceuticals,
Inc. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a
clinical-stage specialty neuropsychiatric pharmaceutical company
dedicated to developing and commercializing innovative
pharmaceutically-produced transdermal cannabinoid treatments for
rare or near-rare neuropsychiatric disorders with high unmet
medical needs. We are dedicated to improving the lives of people
with severe health conditions by developing cannabinoid medicines
designed to meet the rigorous efficacy and safety standards
established by global regulatory agencies. Through the discovery
and development of these potentially life-changing medicines,
Zynerba seeks to improve the lives of patients battling severe,
chronic health conditions including Fragile X syndrome, refractory
epilepsies, Tourette Syndrome, and other neuropsychiatric
disorders. Learn more at www.zynerba.com and follow the Company on
Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Investor ContactWilliam Roberts, Vice
President, Investor Relations and Corporate CommunicationsZynerba
Pharmaceuticals484.581.7489 robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2023 to Apr 2024